Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Laurence Albigès(Université Paris-Saclay), Fabrice Barlési(Hôpital Nord), Jean‐Baptiste Micol(Université Paris-Saclay), Dominique Valteau‐Couanet(Institut Gustave Roussy), Annabelle Stoclin(Institut Gustave Roussy), Jean‐Charles Soria(Inserm), Mathilde Hauchecorne(Université Paris-Saclay), Stéphanie Foulon(Inserm), Benjamin Besse(Institut Gustave Roussy), Christophe Willekens(Université Paris-Saclay), Samy Ammari(Université Paris-Saclay), Nathalie Chaput(Institut Gustave Roussy), Thomas Hueso(Institut Gustave Roussy), Florence Netzer(Université Paris-Saclay), Véronique Saada(Université Paris-Saclay), Corinne Balleyguier(Institut Gustave Roussy), Émeline Colomba(Université Paris-Saclay), Audrey Perret(Université Paris-Saclay), Arnaud Bayle(Université Paris-Saclay), Julien Hadoux(Université Paris-Saclay), Florian Scotté(Université Paris-Saclay), Fanny Pommeret(Université Paris-Saclay), Jean‐Marie Michot(Institut Gustave Roussy), Antoine Hollebecque(Institut Gustave Roussy), Bertrand Gachot(Université Paris-Saclay), Mansouria Merad(Université Paris-Saclay), Roger Sun(Inserm), Frank Griscelli(Université Paris-Saclay), Fabrice André(Inserm), Giulia Baciarello(Université Paris-Saclay), Ludovic Lacroix(Centre National de la Recherche Scientifique)
Cited by 119
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k